{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T21:05:00Z","timestamp":1788123900965,"version":"build-2803163510"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00705-022-05368-z","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T11:04:51Z","timestamp":1644404691000},"page":"751-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Investigational antiviral drugs for the treatment of COVID-19 patients"],"prefix":"10.1007","volume":"167","author":[{"given":"Samineh","family":"Beheshtirouy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz","family":"Khani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Khiali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3653-3653","authenticated-orcid":false,"given":"Taher","family":"Entezari-Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"5368_CR1","doi-asserted-by":"crossref","first-page":"101734","DOI":"10.1016\/j.redox.2020.101734","volume":"37","author":"D Akaberi","year":"2020","unstructured":"Akaberi D, Krambrich J, Ling J, Luni C, Hedenstierna G, J\u00e4rhult JD et al (2020) Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Redox Biol 37:101734","journal-title":"Redox Biol"},{"issue":"1","key":"5368_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2009.09.007","volume":"395","author":"S Akerstr\u00f6m","year":"2009","unstructured":"Akerstr\u00f6m S, Gunalan V, Keng CT, Tan YJ, Mirazimi A (2009) Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology 395(1):1\u20139","journal-title":"Virology"},{"issue":"3","key":"5368_CR3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.antiviral.2006.10.008","volume":"73","author":"S Akerstr\u00f6m","year":"2007","unstructured":"Akerstr\u00f6m S, Mirazimi A, Tan YJ (2007) Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a\/7b, 3a\/3b and S. Antiviral Res 73(3):219\u2013227","journal-title":"Antiviral Res"},{"issue":"9","key":"5368_CR4","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/nano10091699","volume":"10","author":"T Akiyama","year":"2020","unstructured":"Akiyama T, Hirata T, Fujimoto T, Hatakeyama S, Yamazaki R, Nomura T (2020) The natural-mineral-based novel nanomaterial IFMC increases intravascular nitric oxide without its intake: implications for COVID-19 and beyond. Nanomaterials (Basel) 10(9):1699","journal-title":"Nanomaterials (Basel)"},{"issue":"15","key":"5368_CR5","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.3390\/ijms21155224","volume":"21","author":"RA Al-Horani","year":"2020","unstructured":"Al-Horani RA, Kar S, Aliter KF (2020) Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials. Int J Mol Sci 21(15):5224","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5368_CR6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2020.11.008","volume":"74","author":"M Arechederra","year":"2021","unstructured":"Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S et al (2021) ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol 74(4):893\u2013906","journal-title":"J Hepatol"},{"issue":"16","key":"5368_CR7","first-page":"4648","volume":"49","author":"CL Arteaga","year":"1989","unstructured":"Arteaga CL, Brown TD, Kuhn JG, Shen HS, O\u2019Rourke TJ, Beougher K et al (1989) Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). Cancer Res 49(16):4648\u20134653","journal-title":"Cancer Res"},{"issue":"18","key":"5368_CR8","doi-asserted-by":"crossref","first-page":"22241","DOI":"10.1007\/s11356-021-13018-1","volume":"28","author":"YA Attia","year":"2021","unstructured":"Attia YA, El-Saadony MT, Swelum AA, Qattan SYA, Al-Qurashi AD, Asiry KA et al (2021) COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact-an updated review. Environ Sci Pollut Res Int 28(18):22241\u201322264","journal-title":"Environ Sci Pollut Res Int"},{"issue":"1","key":"5368_CR9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13613-020-00769-2","volume":"10","author":"F Bagate","year":"2020","unstructured":"Bagate F, Tuffet S, Masi P, Perier F, Razazi K, de Prost N et al (2020) Rescue therapy with inhaled nitric oxide and almitrine in COVID-19 patients with severe acute respiratory distress syndrome. Ann Intensive Care 10(1):151","journal-title":"Ann Intensive Care"},{"issue":"2","key":"5368_CR10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/v13020271","volume":"13","author":"A Bakovic","year":"2021","unstructured":"Bakovic A, Risner K, Bhalla N, Alem F, Chang TL, Weston WK et al (2021) Brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture. Viruses 13(2):271","journal-title":"Viruses"},{"issue":"1","key":"5368_CR11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/cells10010030","volume":"10","author":"MV Baranov","year":"2020","unstructured":"Baranov MV, Bianchi F, van den Bogaart G (2020) The PIKfyve inhibitor apilimod: a double-edged sword against COVID-19. Cells 10(1):30","journal-title":"Cells"},{"key":"5368_CR12","doi-asserted-by":"crossref","first-page":"635670","DOI":"10.1155\/2015\/635670","volume":"2015","author":"W Barcellini","year":"2015","unstructured":"Barcellini W, Fattizzo B (2015) Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers 2015:635670","journal-title":"Dis Markers"},{"issue":"19","key":"5368_CR13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al (2020) Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med 383(19):1813\u20131826","journal-title":"N Engl J Med"},{"issue":"12","key":"5368_CR14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/ph13120428","volume":"13","author":"MD Bleasel","year":"2020","unstructured":"Bleasel MD, Peterson GM (2020) Emetine is not ipecac: considerations for its use as treatment for SARS-CoV2. Pharmaceuticals (Basel) 13(12):428","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"5368_CR15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"YS Boriskin","year":"2008","unstructured":"Boriskin YS, Leneva IA, P\u00e9cheur EI, Polyak SJ (2008) Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15(10):997\u20131005","journal-title":"Curr Med Chem"},{"issue":"6","key":"5368_CR16","doi-asserted-by":"crossref","first-page":"165759","DOI":"10.1016\/j.bbadis.2020.165759","volume":"1866","author":"S Boukalova","year":"2020","unstructured":"Boukalova S, Hubackova S, Milosevic M, Ezrova Z, Neuzil J, Rohlena J (2020) Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer. Biochim Biophys Acta Mol Basis Dis 1866(6):165759","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"6","key":"5368_CR17","first-page":"669","volume":"4","author":"I Brodsky","year":"1985","unstructured":"Brodsky I, Strayer DR, Krueger LJ, Carter WA (1985) Clinical studies with ampligen (mismatched double-stranded RNA). J Biol Response Mod 4(6):669\u2013675","journal-title":"J Biol Response Mod"},{"issue":"2","key":"5368_CR18","first-page":"185","volume":"10","author":"K Cabala","year":"2020","unstructured":"Cabala K, Earabino J, Pacult P, Uckun F (2020) Rationale for a randomized, placebo-controlled, phase 2 study of Rejuveinix (RJX) in COVID-19 patients with acute lung injury and hypoxemic respiratory failure. Clin Investig (Lond) 10(2):185\u2013189","journal-title":"Clin Investig (Lond)"},{"issue":"6","key":"5368_CR19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2020.12603","volume":"324","author":"A Carf\u00ec","year":"2020","unstructured":"Carf\u00ec A, Bernabei R, Landi F (2020) Persistent symptoms in patients after acute COVID-19. JAMA 324(6):603\u2013605","journal-title":"JAMA"},{"issue":"1","key":"5368_CR20","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202000115","volume":"40","author":"CN Cavasotto","year":"2021","unstructured":"Cavasotto CN, Di Filippo JI (2021) In silico drug repurposing for COVID-19: targeting SARS-CoV-2 proteins through docking and consensus ranking. Mol Inform 40(1):e2000115","journal-title":"Mol Inform"},{"key":"5368_CR21","doi-asserted-by":"crossref","unstructured":"Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al (2020) Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv 2020.03.17.20037432","DOI":"10.1101\/2020.03.17.20037432"},{"issue":"10","key":"5368_CR22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/nu10101521","volume":"10","author":"JR Chen","year":"2018","unstructured":"Chen JR, Ko J, Yeh WJ, Huang WC, Yang HY (2018) Renoprotective effects of antroquinonol in rats with N(\u03c9)-nitro-l-arginine methyl ester-induced hypertension. Nutrients 10(10):1521","journal-title":"Nutrients"},{"issue":"10","key":"5368_CR23","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1086\/425357","volume":"39","author":"L Chen","year":"2004","unstructured":"Chen L, Liu P, Gao H, Sun B, Chao D, Wang F et al (2004) Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis 39(10):1531\u20131535","journal-title":"Clin Infect Dis"},{"issue":"10223","key":"5368_CR24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507\u2013513","journal-title":"Lancet"},{"key":"5368_CR25","doi-asserted-by":"crossref","unstructured":"Chen X, Zhang Y, Zhu B, Zeng J, Hong W, He X, et al (2020) Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study. medRxiv 2020.04.09.20058941","DOI":"10.1101\/2020.04.09.20058941"},{"issue":"2","key":"5368_CR26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bcp.2009.08.022","volume":"79","author":"PC Chiang","year":"2010","unstructured":"Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT et al (2010) Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol 79(2):162\u2013171","journal-title":"Biochem Pharmacol"},{"key":"5368_CR27","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"KT Choy","year":"2020","unstructured":"Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY et al (2020) Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 178:104786","journal-title":"Antiviral Res"},{"issue":"3","key":"5368_CR28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12032-021-01464-3","volume":"38","author":"D Ciardiello","year":"2021","unstructured":"Ciardiello D, Blauensteiner B, Matrone N, Belli V, Mohr T, Vitiello PP et al (2021) Dual inhibition of TGF\u03b2 and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Med Oncol 38(3):24","journal-title":"Med Oncol"},{"issue":"9","key":"5368_CR29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/jir.1997.17.503","volume":"17","author":"MJ Clemens","year":"1997","unstructured":"Clemens MJ, Elia A (1997) The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17(9):503\u2013524","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"5368_CR30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","volume":"6","author":"RM Cox","year":"2021","unstructured":"Cox RM, Wolf JD, Plemper RK (2021) Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 6(1):11\u201318","journal-title":"Nat Microbiol"},{"key":"5368_CR31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fpubh.2020.00232","volume":"8","author":"MA Crane-Godreau","year":"2020","unstructured":"Crane-Godreau MA, Clem KJ, Payne P, Fiering S (2020) Vitamin D deficiency and air pollution exacerbate COVID-19 through suppression of antiviral peptide LL37. Front Public Health 8:232","journal-title":"Front Public Health"},{"key":"5368_CR32","doi-asserted-by":"crossref","first-page":"v583","DOI":"10.1093\/annonc\/mdx390.034","volume":"28","author":"O D'Cruz","year":"2017","unstructured":"D\u2019Cruz O, Lee C, Trieu V, Hwang L (2017) Synergistic antitumor effects of OT-101 (trabedersen), a transforming growth factor-beta 2 (TGF-\u03b22) antisense oligonucleotide (ASO) and chemotherapy in preclinical tumor models. Ann Oncol 28:v583\u2013v584","journal-title":"Ann Oncol"},{"issue":"2","key":"5368_CR33","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2157","volume":"31","author":"MB de Loyola","year":"2021","unstructured":"de Loyola MB, Dos Reis TTA, de Oliveira GXLM, da Fonseca Palmeira J, Arga\u00f1araz GA, Arga\u00f1araz ER (2021) Alpha-1-antitrypsin: a possible host protective factor against Covid-19. Rev Med Virol 31(2):e2157","journal-title":"Rev Med Virol"},{"key":"5368_CR34","unstructured":"de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O\u2019Connor R, et al (2020) Comparative study of a 3CL (pro) inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models. bioRxiv"},{"key":"5368_CR35","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2020.38.15_suppl.8017","volume":"38","author":"C Diefenbach","year":"2020","unstructured":"Diefenbach C, Cohen J, Harb W, Ansell S, Nastoupil L, Abramson J et al (2020) Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers. J Clin Oncol 38:8017","journal-title":"J Clin Oncol"},{"issue":"6","key":"5368_CR36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1183\/09031936.00159408","volume":"33","author":"A Dirksen","year":"2009","unstructured":"Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB et al (2009) Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 33(6):1345\u20131353","journal-title":"Eur Respir J"},{"key":"5368_CR37","doi-asserted-by":"crossref","unstructured":"Dunia A, Sanaa B (2020) The potential role of inhaled nitric oxide in managing COVID-19 associated lung complications review of literature. Int J Respir Pulm Med 7(4)","DOI":"10.23937\/2378-3516\/1410145"},{"issue":"8","key":"5368_CR38","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","volume":"58","author":"J Dyall","year":"2014","unstructured":"Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al (2014) Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58(8):4885\u20134893","journal-title":"Antimicrob Agents Chemother"},{"key":"5368_CR39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2020.09.014","volume":"141","author":"K El Bairi","year":"2020","unstructured":"El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B et al (2020) Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer 141:40\u201361","journal-title":"Eur J Cancer"},{"key":"5368_CR40","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"AA Elfiky","year":"2020","unstructured":"Elfiky AA (2020) Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci 253:117592","journal-title":"Life Sci"},{"issue":"3","key":"5368_CR41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0166-3542(01)00150-4","volume":"51","author":"RJ Essey","year":"2001","unstructured":"Essey RJ, McDougall BR, Robinson WE Jr (2001) Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Res 51(3):189\u2013202","journal-title":"Antiviral Res"},{"key":"5368_CR42","first-page":"40","volume":"5","author":"VM Gagarinova","year":"1993","unstructured":"Gagarinova VM, Ignat\u2019eva GS, Sinitskaia LV, Ivanova AM, Rodina MA, Tur\u2019eva AV (1993) The new chemical preparation arbidol: its prophylactic efficacy during influenza epidemics. Zh Mikrobiol Epidemiol Immunobiol 5:40\u201343","journal-title":"Zh Mikrobiol Epidemiol Immunobiol"},{"issue":"13","key":"5368_CR43","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","volume":"129","author":"S Gayle","year":"2017","unstructured":"Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P et al (2017) Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood 129(13):1768\u20131778","journal-title":"Blood"},{"issue":"6","key":"5368_CR44","first-page":"Cd002787","volume":"2016","author":"F Gebistorf","year":"2016","unstructured":"Gebistorf F, Karam O, Wetterslev J, Afshari A (2016) Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev 2016(6):Cd002787","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"5368_CR45","doi-asserted-by":"crossref","first-page":"A2446","DOI":"10.1016\/j.chest.2020.09.031","volume":"158","author":"M Goldshtein","year":"2020","unstructured":"Goldshtein M, Lerner O, Kalaora R, Yarkoni S, Dekel E, Confino H et al (2020) Nitric oxide is a powerful anti-coronavirus-inhaled agent that acts within hours. Chest 158(4):A2446\u2013A2447","journal-title":"Chest"},{"issue":"Suppl 1","key":"5368_CR46","doi-asserted-by":"crossref","first-page":"S649","DOI":"10.1093\/ofid\/ofaa439.1449","volume":"7","author":"SS Good","year":"2020","unstructured":"Good SS, Moussa A, Zhou X-J, Pietropaolo K, Sommadossi J-P (2020) 1265. AT-527, an oral purine nucleotide prodrug exhibiting potent in vitro antiviral activity against human coronaviruses, including SARS-CoV-2. Open Forum Infect Dis 7(Suppl 1):S649","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"5368_CR47","volume":"15","author":"SS Good","year":"2020","unstructured":"Good SS, Moussa A, Zhou XJ, Pietropaolo K, Sommadossi JP (2020) Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One 15(1):e0227104","journal-title":"PLoS One"},{"key":"5368_CR48","doi-asserted-by":"crossref","unstructured":"Good SS, Westover J, Jung KH, Zhou XJ, Moussa A, La Colla P et al (2021) AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother 65(4)","DOI":"10.1128\/AAC.02479-20"},{"issue":"8","key":"5368_CR49","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.4049\/jimmunol.178.8.5200","volume":"178","author":"BB Gowen","year":"2007","unstructured":"Gowen BB, Wong MH, Jung KH, Sanders AB, Mitchell WM, Alexopoulou L et al (2007) TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 178(8):5200\u20135208","journal-title":"J Immunol"},{"issue":"6","key":"5368_CR50","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1073\/pnas.56.6.1867","volume":"56","author":"AP Grollman","year":"1966","unstructured":"Grollman AP (1966) Structural basis for inhibition of protein synthesis by emetine and cycloheximide based on an analogy between ipecac alkaloids and glutarimide antibiotics. Proc Natl Acad Sci USA 56(6):1867\u20131874","journal-title":"Proc Natl Acad Sci USA"},{"issue":"33","key":"5368_CR51","doi-asserted-by":"crossref","first-page":"11388","DOI":"10.1074\/jbc.RA120.012635","volume":"295","author":"A Harbig","year":"2020","unstructured":"Harbig A, Mernberger M, Bittel L, Pleschka S, Schughart K, Steinmetzer T et al (2020) Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airways. J Biol Chem 295(33):11388\u201311407","journal-title":"J Biol Chem"},{"key":"5368_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.niox.2020.06.005","volume":"103","author":"G Hedenstierna","year":"2020","unstructured":"Hedenstierna G, Chen L, Hedenstierna M, Lieberman R, Fine DH (2020) Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19. Nitric Oxide 103:1\u20133","journal-title":"Nitric Oxide"},{"issue":"8","key":"5368_CR53","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.biopha.2014.09.008","volume":"68","author":"CL Ho","year":"2014","unstructured":"Ho CL, Wang JL, Lee CC, Cheng HY, Wen WC, Cheng HH et al (2014) Antroquinonol blocks Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells. Biomed Pharmacother 68(8):1007\u20131014","journal-title":"Biomed Pharmacother"},{"key":"5368_CR54","doi-asserted-by":"crossref","unstructured":"Hopp M-T, Domingo-Fern\u00e1ndez D, Gadiya Y, Detzel MS, Schmalohr BF, Steinbock F et al (2020) Unravelling the debate on heme effects in COVID-19 infections. bioRxiv 2020.06.09.142125","DOI":"10.1101\/2020.06.09.142125"},{"issue":"1","key":"5368_CR55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jmv.26256","volume":"93","author":"D Huang","year":"2021","unstructured":"Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z (2021) Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Med Virol 93(1):481\u2013490","journal-title":"J Med Virol"},{"key":"5368_CR56","doi-asserted-by":"crossref","unstructured":"Huang H, Guan L, Yang Y, Grange JML, Tang G, Xu Y et al (2020) Chloroquine, arbidol (umifenovir) or lopinavir\/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study. Res Square","DOI":"10.21203\/rs.3.rs-24667\/v1"},{"key":"5368_CR57","volume":"34","author":"L Hwang","year":"2016","unstructured":"Hwang L, Ng K, Wang W, Trieu V (2016) OT-101: An anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies. J Clin Oncol 34:e1527","journal-title":"J Clin Oncol"},{"issue":"45","key":"5368_CR58","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1016\/j.vaccine.2009.04.074","volume":"27","author":"T Ichinohe","year":"2009","unstructured":"Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H (2009) PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 27(45):6276\u20136279","journal-title":"Vaccine"},{"key":"5368_CR59","doi-asserted-by":"crossref","unstructured":"Idris MM, Banu S, Siva AB, Nagaraj R (2020) Downregulation of defensin genes in SARS-CoV-2 infection. medRxiv 2020.09.21.20195537","DOI":"10.1101\/2020.09.21.20195537"},{"key":"5368_CR60","doi-asserted-by":"crossref","first-page":"104836","DOI":"10.1016\/j.micpath.2021.104836","volume":"154","author":"A Jafarzadeh","year":"2021","unstructured":"Jafarzadeh A, Nemati M (2021) Jafarzadeh S (2021) Contribution of STAT3 to the pathogenesis of COVID-19. Microb Pathog 154:104836","journal-title":"Microb Pathog"},{"issue":"9","key":"5368_CR61","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jiph.2020.07.013","volume":"13","author":"S Jomah","year":"2020","unstructured":"Jomah S, Asdaq SMB, Al-Yamani MJ (2020) Clinical efficacy of antivirals against novel coronavirus (COVID-19): a review. J Infect Public Health 13(9):1187\u20131195","journal-title":"J Infect Public Health"},{"issue":"34","key":"5368_CR62","doi-asserted-by":"crossref","first-page":"20803","DOI":"10.1073\/pnas.2007837117","volume":"117","author":"YL Kang","year":"2020","unstructured":"Kang YL, Chou YY, Rothlauf PW, Liu Z, Soh TK, Cureton D et al (2020) Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc Natl Acad Sci USA 117(34):20803\u201320813","journal-title":"Proc Natl Acad Sci USA"},{"key":"5368_CR63","doi-asserted-by":"crossref","first-page":"104874","DOI":"10.1016\/j.phrs.2020.104874","volume":"157","author":"MT Kelleni","year":"2020","unstructured":"Kelleni MT (2020) Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management. Pharmacol Res 157:104874","journal-title":"Pharmacol Res"},{"issue":"4","key":"5368_CR64","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijid.2004.04.012","volume":"8","author":"E Keyaerts","year":"2004","unstructured":"Keyaerts E, Vijgen L, Chen L, Maes P, Hedenstierna G, Van Ranst M (2004) Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. Int J Infect Dis 8(4):223\u2013226","journal-title":"Int J Infect Dis"},{"key":"5368_CR65","doi-asserted-by":"crossref","first-page":"105056","DOI":"10.1016\/j.antiviral.2021.105056","volume":"189","author":"R Kumar","year":"2021","unstructured":"Kumar R, Afsar M, Khandelwal N, Chander Y, Riyesh T, Dedar RK et al (2021) Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E. Antiviral Res 189:105056","journal-title":"Antiviral Res"},{"issue":"1","key":"5368_CR66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3940(98)00266-3","volume":"247","author":"PA Li","year":"1998","unstructured":"Li PA, Howlett W, He QP, Miyashita H, Siddiqui M, Shuaib A (1998) Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett 247(1):17\u201320","journal-title":"Neurosci Lett"},{"issue":"2","key":"5368_CR67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","volume":"10","author":"X Li","year":"2020","unstructured":"Li X, Geng M, Peng Y, Meng L, Lu S (2020) Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 10(2):102\u2013108","journal-title":"J Pharm Anal"},{"issue":"1","key":"5368_CR68","first-page":"105","volume":"1","author":"Y Li","year":"2020","unstructured":"Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y et al (2020) Efficacy and Safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial. Medicine (N Y) 1(1):105\u201313.e4","journal-title":"Medicine (N Y)"},{"issue":"7","key":"5368_CR69","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cmi.2020.04.026","volume":"26","author":"N Lian","year":"2020","unstructured":"Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q (2020) Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect 26(7):917\u2013921","journal-title":"Clin Microbiol Infect"},{"key":"5368_CR70","unstructured":"Liu Q, Fang X, Tian L, Chung U, Chen X, Wang K et al (2020) The effect of arbidol hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world data from three hospitals in Wuhan. medRxiv 2020.04.11.20056523."},{"issue":"8","key":"5368_CR71","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/aps.2013.54","volume":"34","author":"Q Liu","year":"2013","unstructured":"Liu Q, Xiong HR, Lu L, Liu YY, Luo F, Hou W et al (2013) Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacol Sin 34(8):1075\u20131083","journal-title":"Acta Pharmacol Sin"},{"key":"5368_CR72","doi-asserted-by":"crossref","first-page":"173748","DOI":"10.1016\/j.ejphar.2020.173748","volume":"891","author":"AS Lokhande","year":"2021","unstructured":"Lokhande AS, Devarajan PV (2021) A review on possible mechanistic insights of nitazoxanide for repurposing in COVID-19. Eur J Pharmacol 891:173748","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5368_CR73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1574892812666171108124218","volume":"13","author":"ML Lolli","year":"2018","unstructured":"Lolli ML, Sainas S, Pippione AC, Giorgis M, Boschi D, Dosio F (2018) Use of human dihydroorotate dehydrogenase (hDHODH) inhibitors in autoimmune diseases and new perspectives in cancer therapy. Recent Pat Anticancer Drug Discov 13(1):86\u2013105","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"5","key":"5368_CR74","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/aas.13757","volume":"65","author":"C Lotz","year":"2021","unstructured":"Lotz C, Muellenbach RM, Meybohm P, Mutlak H, Lepper PM, Rolfes CB et al (2021) Effects of inhaled nitric oxide in COVID-19-induced ARDS\u2014is it worthwhile? Acta Anaesthesiol Scand 65(5):629\u2013632","journal-title":"Acta Anaesthesiol Scand"},{"key":"5368_CR75","unstructured":"Mahshid A, Hesamoddin H (2020) Molecular mechanisms of galidesivir as a potential antiviral treatment for COVID-19. J Pharm Care 8(3)"},{"key":"5368_CR76","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-065X.1993.tb00654.x","volume":"136","author":"L Makowka","year":"1993","unstructured":"Makowka L, Sher LS, Cramer DV (1993) The development of Brequinar as an immunosuppressive drug for transplantation. Immunol Rev 136:51\u201370","journal-title":"Immunol Rev"},{"issue":"17","key":"5368_CR77","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/bioinformatics\/btab130","volume":"37","author":"R Mall","year":"2021","unstructured":"Mall R, Elbasir A, Almeer H, Islam Z, Kolatkar PR, Chawla S et al (2021) A modelling framework for embedding-based predictions for compound-viral protein activity. Bioinformatics 37(17):2544\u20132555","journal-title":"Bioinformatics"},{"key":"5368_CR78","doi-asserted-by":"crossref","unstructured":"Martinez MA (2021) Plitidepsin: a repurposed drug for the treatment of COVID-19. Antimicrob Agents Chemother 65(4)","DOI":"10.1128\/AAC.00200-21"},{"issue":"1","key":"5368_CR79","doi-asserted-by":"crossref","first-page":"L35","DOI":"10.1152\/ajplung.00170.2020","volume":"319","author":"PR Martins-Filho","year":"2020","unstructured":"Martins-Filho PR, Barreto-Alves JA, Fakhouri R (2020) Potential role for nitazoxanide in treating SARS-CoV-2 infection. Am J Physiol Lung Cell Mol Physiol 319(1):L35\u2013L36","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"5368_CR80","unstructured":"Maury PW (2021) Targeting the receptor AXL by bemcentinib prevents SARS-CoV-2 infection. Accessed March 6, 2021"},{"key":"5368_CR81","doi-asserted-by":"crossref","unstructured":"Mir JM, Maurya RC (2020) Nitric oxide boosters as defensive agents against COVID-19 infection: an opinion. J Biomol Struct Dyn 1\u20137","DOI":"10.1080\/07391102.2020.1852969"},{"issue":"6","key":"5368_CR82","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1586\/17512433.2016.1172960","volume":"9","author":"WM Mitchell","year":"2016","unstructured":"Mitchell WM (2016) Efficacy of rintatolimod in the treatment of chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/ME). Expert Rev Clin Pharmacol 9(6):755\u2013770","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"5368_CR83","doi-asserted-by":"crossref","first-page":"9805","DOI":"10.1038\/s41598-018-27855-7","volume":"8","author":"RLS Neris","year":"2018","unstructured":"Neris RLS, Figueiredo CM, Higa LM, Araujo DF, Carvalho CAM, Ver\u00e7oza BRF et al (2018) Co-protoporphyrin IX and Sn-protoporphyrin IX inactivate Zika, Chikungunya and other arboviruses by targeting the viral envelope. Sci Rep 8(1):9805","journal-title":"Sci Rep"},{"issue":"1","key":"5368_CR84","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12879-020-05698-w","volume":"20","author":"M Nojomi","year":"2020","unstructured":"Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A et al (2020) Effect of arbidol (umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis 20(1):954","journal-title":"BMC Infect Dis"},{"key":"5368_CR85","doi-asserted-by":"crossref","unstructured":"Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut N et al (2021) Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother 65(5)","DOI":"10.1128\/AAC.02428-20"},{"issue":"1\u20133","key":"5368_CR86","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0300-483X(98)00026-2","volume":"127","author":"C Pally","year":"1998","unstructured":"Pally C, Smith D, Jaffee B, Magolda R, Zehender H, Dorobek B et al (1998) Side effects of brequinar and brequinar analogues, in combination with cyclosporine, in the rat. Toxicology 127(1\u20133):207\u2013222","journal-title":"Toxicology"},{"issue":"6","key":"5368_CR87","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","volume":"90","author":"EI P\u00e9cheur","year":"2016","unstructured":"P\u00e9cheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M et al (2016) The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol 90(6):3086\u20133092","journal-title":"J Virol"},{"issue":"3","key":"5368_CR88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00175293","volume":"5","author":"GJ Peters","year":"1987","unstructured":"Peters GJ, Sharma SL, Laurensse E, Pinedo HM (1987) Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390). Invest New Drugs 5(3):235\u2013244","journal-title":"Invest New Drugs"},{"key":"5368_CR89","doi-asserted-by":"crossref","unstructured":"Ramasamy S, Subbian S (2021) Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis. Clin Microbiol Rev 34(3)","DOI":"10.1128\/CMR.00299-20"},{"issue":"6","key":"5368_CR90","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1128\/JVI.72.6.4547-4551.1998","volume":"72","author":"CS Reiss","year":"1998","unstructured":"Reiss CS, Komatsu T (1998) Does nitric oxide play a critical role in viral infections? J Virol 72(6):4547\u20134551","journal-title":"J Virol"},{"key":"5368_CR91","first-page":"45","volume":"4","author":"S Rele","year":"2020","unstructured":"Rele S (2020) Emerging outbreaks and epidemic threats: the practicality and limitations in the development and manufacturing of treatments for coronavirus (covid-19). Polymorphism 4:45\u201352","journal-title":"Polymorphism"},{"issue":"1","key":"5368_CR92","doi-asserted-by":"crossref","first-page":"014001","DOI":"10.1088\/1752-7163\/abc302","volume":"15","author":"FLM Ricciardolo","year":"2020","unstructured":"Ricciardolo FLM, Bertolini F, Carriero V, H\u00f6gman M (2020) Nitric oxide\u2019s physiologic effects and potential as a therapeutic agent against COVID-19. J Breath Res 15(1):014001","journal-title":"J Breath Res"},{"key":"5368_CR93","doi-asserted-by":"crossref","unstructured":"Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Burgstaller-Muehlbacher S et al (2020) A large-scale drug repositioning survey for SARS-CoV-2 antivirals. bioRxiv: the preprint server for biology 2020.04.16.044016","DOI":"10.1101\/2020.04.16.044016"},{"issue":"7827","key":"5368_CR94","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"L Riva","year":"2020","unstructured":"Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L et al (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586(7827):113\u2013119","journal-title":"Nature"},{"key":"5368_CR95","unstructured":"Rocco PRM, Silva PL, Cruz FF, Junior M, Tierno P, Moura MA et al (2021) Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J"},{"issue":"1","key":"5368_CR96","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41467-021-22580-8","volume":"12","author":"K Rosenke","year":"2021","unstructured":"Rosenke K, Hansen F, Schwarz B, Feldmann F, Haddock E, Rosenke R et al (2021) Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun 12(1):2295","journal-title":"Nat Commun"},{"key":"5368_CR97","doi-asserted-by":"crossref","unstructured":"Rudrapal M, Khairnar SJ, Jadhav AG (2020) Drug repurposing (DR): an emerging approach in drug discovery. drug repurposing-hypothesis, molecular aspects and therapeutic applications IntechOpen","DOI":"10.5772\/intechopen.93193"},{"issue":"5","key":"5368_CR98","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14787210.2017.1305888","volume":"15","author":"C Salata","year":"2017","unstructured":"Salata C, Calistri A, Parolin C, Baritussio A, Pal\u00f9 G (2017) Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther 15(5):483\u2013492","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5368_CR99","doi-asserted-by":"crossref","unstructured":"Senapati S, Banerjee P, Bhagavatula S, Kushwaha PP, Kumar S (2021) Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. J Genet 100(1)","DOI":"10.1007\/s12041-021-01262-w"},{"key":"5368_CR100","doi-asserted-by":"crossref","unstructured":"Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML et al (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12(541)","DOI":"10.1126\/scitranslmed.abb5883"},{"issue":"12","key":"5368_CR101","doi-asserted-by":"crossref","first-page":"e00023","DOI":"10.1128\/JVI.00023-19","volume":"93","author":"L Shen","year":"2019","unstructured":"Shen L, Niu J, Wang C, Huang B, Wang W, Zhu N et al (2019) High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. J Virol 93(12):e00023-e119","journal-title":"J Virol"},{"issue":"3","key":"5368_CR102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031334","volume":"7","author":"DR Strayer","year":"2012","unstructured":"Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ et al (2012) A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One 7(3):e31334","journal-title":"PLoS One"},{"key":"5368_CR103","doi-asserted-by":"crossref","first-page":"113201","DOI":"10.1016\/j.ejmech.2021.113201","volume":"213","author":"L Tian","year":"2021","unstructured":"Tian L, Qiang T, Liang C, Ren X, Jia M, Zhang J et al (2021) RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur J Med Chem 213:113201","journal-title":"Eur J Med Chem"},{"issue":"1","key":"5368_CR104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12929-020-00703-5","volume":"28","author":"IP Trougakos","year":"2021","unstructured":"Trougakos IP, Stamatelopoulos K, Terpos E, Tsitsilonis OE, Aivalioti E, Paraskevis D et al (2021) Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci 28(1):9","journal-title":"J Biomed Sci"},{"key":"5368_CR105","first-page":"35","volume":"10","author":"F Uckun","year":"2020","unstructured":"Uckun F, Hwang L, Trieu V (2020) Selectively targeting TGF-2 with Trabedersen\/OT-101 in treatment of evolving and mild ards inCOVID-19. Clin Investig 10:35\u201344","journal-title":"Clin Investig"},{"issue":"1","key":"5368_CR106","first-page":"1","volume":"3","author":"FM Uckun","year":"2020","unstructured":"Uckun FM, Trieu V (2020) Targeting transforming growth factor-beta for treatment of COVID-19-associated Kawasaki disease in children. Clin Res Pediatr 3(1):1\u20133","journal-title":"Clin Res Pediatr"},{"key":"5368_CR107","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3389\/fbioe.2020.00916","volume":"8","author":"H Uluda\u011f","year":"2020","unstructured":"Uluda\u011f H, Parent K, Aliabadi HM, Haddadi A (2020) Prospects for RNAi therapy of COVID-19. Front Bioeng Biotechnol 8:916","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"5368_CR108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s43556-020-00018-9","volume":"1","author":"A Wang","year":"2020","unstructured":"Wang A, Sun Y, Liu Q, Wu H, Liu J, He J et al (2020) Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences. Molecular Biomedicine 1(1):14","journal-title":"Molecular Biomedicine"},{"key":"5368_CR109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","volume":"6","author":"X Wang","year":"2020","unstructured":"Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H et al (2020) The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 6:28","journal-title":"Cell Discov"},{"issue":"7496","key":"5368_CR110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","volume":"508","author":"TK Warren","year":"2014","unstructured":"Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA et al (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402\u2013405","journal-title":"Nature"},{"issue":"Suppl 1","key":"5368_CR111","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/15412555.2013.764402","volume":"10","author":"MD Wewers","year":"2013","unstructured":"Wewers MD, Crystal RG (2013) Alpha-1 antitrypsin augmentation therapy. COPD 10(Suppl 1):64\u201367","journal-title":"COPD"},{"issue":"6532","key":"5368_CR112","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.abf4058","volume":"371","author":"KM White","year":"2021","unstructured":"White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E et al (2021) Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science 371(6532):926\u2013931","journal-title":"Science"},{"issue":"11","key":"5368_CR113","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000277","volume":"2","author":"SB Wiegand","year":"2020","unstructured":"Wiegand SB, Safaee Fakhr B, Carroll RW, Zapol WM, Kacmarek RM, Berra L (2020) Rescue treatment with high-dose gaseous nitric oxide in spontaneously breathing patients with severe coronavirus disease 2019. Crit Care Explor 2(11):e0277","journal-title":"Crit Care Explor"},{"issue":"1","key":"5368_CR114","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s13063-020-04584-9","volume":"21","author":"T Wilkinson","year":"2020","unstructured":"Wilkinson T, Dixon R, Page C, Carroll M, Griffiths G, Ho LP et al (2020) ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of covid-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial. Trials 21(1):691","journal-title":"Trials"},{"issue":"10","key":"5368_CR115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","volume":"11","author":"R Xiong","year":"2020","unstructured":"Xiong R, Zhang L, Li S, Sun Y, Ding M, Wang Y et al (2020) Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell 11(10):723\u2013739","journal-title":"Protein Cell"},{"issue":"1","key":"5368_CR116","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","volume":"9","author":"Y Xiong","year":"2020","unstructured":"Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A et al (2020) Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 9(1):761\u2013770","journal-title":"Emerg Microbes Infect"},{"key":"5368_CR117","doi-asserted-by":"crossref","unstructured":"Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W et al (2020) Clinical efficacy of arbidol in patients with 2019 novel coronavirus-infected pneumonia: a retrospective cohort study. SSRN J","DOI":"10.2139\/ssrn.3542148"},{"issue":"4\u20135","key":"5368_CR118","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.micinf.2020.05.012","volume":"22","author":"P Xu","year":"2020","unstructured":"Xu P, Huang J, Fan Z, Huang W, Qi M, Lin X et al (2020) Arbidol\/IFN-\u03b12b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect 22(4\u20135):200\u2013205","journal-title":"Microbes Infect"},{"issue":"10","key":"5368_CR119","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13238-020-00769-9","volume":"11","author":"Y Xu","year":"2020","unstructured":"Xu Y, Jiang H (2020) Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase. Protein Cell 11(10):699\u2013702","journal-title":"Protein Cell"},{"issue":"4","key":"5368_CR120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-2600(21)00018-7","volume":"9","author":"C Yang","year":"2021","unstructured":"Yang C, Chapman KR, Wong A, Liu M (2021) \u03b11-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action. Lancet Respir Med 9(4):337\u2013339","journal-title":"Lancet Respir Med"},{"key":"5368_CR121","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fpubh.2020.00249","volume":"8","author":"C Yang","year":"2020","unstructured":"Yang C, Ke C, Yue D, Li W, Hu Z, Liu W et al (2020) Effectiveness of arbidol for COVID-19 prevention in health professionals. Front Public Health 8:249","journal-title":"Front Public Health"},{"key":"5368_CR122","doi-asserted-by":"crossref","first-page":"615398","DOI":"10.3389\/fphar.2020.615398","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang C, Keshavjee S, Liu M (2020) Alpha-1 antitrypsin for COVID-19 treatment: dual role in antiviral infection and anti-inflammation. Front Pharmacol 11:615398","journal-title":"Front Pharmacol"},{"key":"5368_CR123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41421-018-0034-1","volume":"4","author":"S Yang","year":"2018","unstructured":"Yang S, Xu M, Lee EM, Gorshkov K, Shiryaev SA, He S et al (2018) Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov 4:31","journal-title":"Cell Discov"},{"issue":"8","key":"5368_CR124","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jnutbio.2011.04.015","volume":"23","author":"CC Yu","year":"2012","unstructured":"Yu CC, Chiang PC, Lu PH, Kuo MT, Wen WC, Chen P et al (2012) Antroquinonol, a natural ubiquinone derivative, induces a cross talk between apoptosis, autophagy and senescence in human pancreatic carcinoma cells. J Nutr Biochem 23(8):900\u2013907","journal-title":"J Nutr Biochem"},{"issue":"1","key":"5368_CR125","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1164\/rccm.202004-0937LE","volume":"202","author":"RT Zamanian","year":"2020","unstructured":"Zamanian RT, Pollack CV Jr, Gentile MA, Rashid M, Fox JC, Mahaffey KW et al (2020) Outpatient inhaled nitric oxide in a patient with vasoreactive idiopathic pulmonary arterial hypertension and COVID-19 infection. Am J Respir Crit Care Med 202(1):130\u2013132","journal-title":"Am J Respir Crit Care Med"},{"key":"5368_CR126","doi-asserted-by":"crossref","first-page":"111352","DOI":"10.1016\/j.biopha.2021.111352","volume":"137","author":"PK Zarandi","year":"2021","unstructured":"Zarandi PK, Zinatizadeh MR, Zinatizadeh M, Yousefi MH, Rezaei N (2021) SARS-CoV-2: from the pathogenesis to potential anti-viral treatments. Biomed Pharmacother 137:111352","journal-title":"Biomed Pharmacother"},{"key":"5368_CR127","doi-asserted-by":"crossref","first-page":"112687","DOI":"10.1016\/j.ejmech.2020.112687","volume":"205","author":"L Zheng","year":"2020","unstructured":"Zheng L, Zhang L, Huang J, Nandakumar KS, Liu S, Cheng K (2020) Potential treatment methods targeting 2019-nCoV infection. Eur J Med Chem 205:112687","journal-title":"Eur J Med Chem"},{"issue":"1","key":"5368_CR128","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","volume":"81","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T et al (2020) Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19. J Infect 81(1):e21\u2013e23","journal-title":"J Infect"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05368-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-022-05368-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05368-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:37:35Z","timestamp":1700203055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-022-05368-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":128,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5368"],"URL":"https:\/\/doi.org\/10.1007\/s00705-022-05368-z","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"27 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}